Eliquis Delay Fuels Speculation About Advisory Committee Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
Three-month user fee extension for Bristol-Myers Squibb and Pfizer’s novel oral anticoagulant apixaban raises questions about whether an advisory committee panel will be convened after all, though the companies say none has been scheduled at this time.